Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation.


Journal

Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055

Informations de publication

Date de publication:
13 11 2020
Historique:
received: 20 07 2020
revised: 24 08 2020
accepted: 07 09 2020
pubmed: 11 9 2020
medline: 27 5 2021
entrez: 10 9 2020
Statut: ppublish

Résumé

Accumulating evidence supports the fact that the mere presence of mucinous differentiation in colorectal cancer (CRC), rather than its proportion, is a more accurate representative of a particular CRC subtype with distinct clinical and molecular features. In addition, the prognostic significance of the mucinous carcinoma (MC) subtype remains poorly understood and biomarkers have been barely explored in this disease. Herein, we have performed a systematic and comprehensive analysis in MCs and non-MCs and identified a panel of microRNAs (miRNAs) that are differentially expressed between these two subtypes of CRC. Next, we interrogated their clinical significance and demonstrated their robust diagnostic and prognostic clinical ability in CRCs with mucinous differentiation. Finally, we established an integrative risk-assessment model by combining the miRNA-based risk scores together with TNM staging, which was a superior predictor of prognosis in mucinous CRC patients. Collectively, we report a novel miRNA biomarker panel for the identification and predicting survival in CRC patients with mucinous differentiation.

Identifiants

pubmed: 32911537
pii: 5903857
doi: 10.1093/carcin/bgaa097
pmc: PMC7896109
doi:

Substances chimiques

Biomarkers, Tumor 0
MicroRNAs 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1498-1506

Subventions

Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184792
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Références

Oncol Rep. 1999 Mar-Apr;6(2):409-14
pubmed: 10023012
Genome Med. 2013 Dec 30;5(12):111
pubmed: 24373327
Int J Oncol. 2005 Oct;27(4):957-64
pubmed: 16142311
Oncol Lett. 2017 Jul;14(1):830-836
pubmed: 28693239
Curr Pharmacol Rep. 2015 Dec;1(6):355-364
pubmed: 27867838
Clin Epigenetics. 2011 Aug;2(2):85-96
pubmed: 22704331
Clin Cancer Res. 2000 May;6(5):1909-16
pubmed: 10815915
J Pathol Clin Res. 2014 Nov 05;1(1):3-17
pubmed: 27499889
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
PLoS One. 2016 Jun 06;11(6):e0156871
pubmed: 27271572
Ann Surg Oncol. 2014 Sep;21(9):2963-70
pubmed: 24728741
Ann Surg Oncol. 2012 Sep;19(9):2814-21
pubmed: 22476818
Anticancer Res. 2013 Oct;33(10):4611-7
pubmed: 24123038
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
pubmed: 21647195
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
pubmed: 16461460
Br J Cancer. 2013 May 28;108(10):1978-84
pubmed: 23652310
Nat Rev Clin Oncol. 2016 Jun;13(6):361-9
pubmed: 26323388
Int J Colorectal Dis. 2011 Nov;26(11):1415-22
pubmed: 21739196
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Mod Pathol. 2020 Jul;33(7):1420-1432
pubmed: 32047231
Cell Cycle. 2008 Oct;7(20):3143-8
pubmed: 18843198
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Surg Today. 2016 Mar;46(3):303-8
pubmed: 25794995
J Cell Physiol. 2018 Feb;233(2):901-913
pubmed: 28092102
J Crohns Colitis. 2016 Jul;10(7):837-49
pubmed: 26818658
Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):822-31
pubmed: 20200425
Oncogene. 2012 Oct 25;31(43):4577-87
pubmed: 22266873

Auteurs

Juan Ruiz-Bañobre (J)

Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.
Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.
Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute and Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.

Roshni Roy (R)

Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute and Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.

Miren Alustiza Fernández (M)

Laboratorio de Investigación, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

Óscar Murcia (Ó)

Laboratorio de Investigación, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Digestive Medicine Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

Rodrigo Jover (R)

Laboratorio de Investigación, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Digestive Medicine Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

Miguel Pera (M)

Section of Colon and Rectal Surgery, Department of Surgery, Hospital del Mar (IMIM), Barcelona, Spain.

Francesc Balaguer (F)

Gastroenterology, Hospital Clinic of Barcelona, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD), Barcelona, Spain.

Rafael López-López (R)

Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.
Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.

Ajay Goel (A)

Center for Gastrointestinal Research; Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute and Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.
Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH